Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
Abstract
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.Downloads
Download data is not yet available.

Published
2013-07-24
Keywords:
Certolizumab pegol, Axial spondyloarthritis, Magnetic resonance.
Statistics
- Abstract views: 2209
- PDF: 479
How to Cite
Spadaro, A., Scarno, A., Carboni, A., Perrotta, F., Catalano, C., Lubrano, E., & Valesini, G. (2013). Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo, 65(3), 134-137. https://doi.org/10.4081/reumatismo.2013.134
Copyright (c) 2013 A. Spadaro, A. Scarno, A. Carboni, F.M. Perrotta, C. Catalano, E. Lubrano, G. Valesini

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.